MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.pan.2018.11.002

Медицинская библиотека · Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2018

Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.

Ramsey Mitchell L, Talbert Erin, Ahn Daniel, Bekaii-Saab Tanios, Badi Niharika, Bloomston P Mark, Conwell Darwin L, Cruz-Monserrate Zobeida, Dillhoff Mary, Farren Matthew R, Hinton Alice, Krishna Somashekar G, Lesinski Gregory B, Mace Thomas, Manilchuk Andrei, Noonan Anne, Pawlik Timothy M, Rajasekera Priyani V, Schmidt Carl, Guttridge Denis, Hart Phil A

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Cachexia is a wasting syndrome characterized by involuntary loss of >5% body weight due to depletion of adipose and skeletal muscle mass. In cancer, the pro-inflammatory cytokine interleukin-6 (IL-6) is considered a mediator of cachexia and a potential biomarker, but the relationship between IL-6, weight loss, and cancer stage is unknown. In this study we sought to evaluate IL-6 as a biomarker of cancer cachexia while accounting for disease progression.

METHODS

We retrospectively studied 136 subjects with biopsy-proven pancreatic ductal adenocarcinoma (PDAC), considering the high prevalence of cachexia is this population. Clinical data were abstracted from subjects in all cancer stages, and plasma IL-6 levels were measured using a multiplex array and a more sensitive ELISA. Data were evaluated with univariate comparisons, including Kaplan-Meier survival curves, and multivariate Cox survival models.

RESULTS

On multiplex, a total of 43 (31.4%) subjects had detectable levels of plasma IL-6, while by ELISA all subjects had detectable IL-6 levels. We found that increased plasma IL-6 levels, defined as detectable for multiplex and greater than median for ELISA, were not associated with weight loss at diagnosis, but rather with the presence of metastasis (p < 0.001 for multiplex and p = 0.007 for ELISA). Further, while >5% weight loss was not associated with worse survival, increased plasma IL-6 by either methodology was.

CONCLUSION

Circulating IL-6 levels do not correlate with cachexia (when defined by weight loss), but rather with advanced cancer stage. This suggests that IL-6 may mediate wasting, but should not be considered a diagnostic biomarker for PDAC-induced cachexia.

Для цитирования: Ramsey Mitchell L, Talbert Erin, Ahn Daniel, Bekaii-Saab Tanios, Badi Niharika, Bloomston P Mark, Conwell Darwin L, Cruz-Monserrate Zobeida, Dillhoff Mary, Farren Matthew R, Hinton Alice, Krishna Somashekar G, Lesinski Gregory B, Mace Thomas, Manilchuk Andrei, Noonan Anne, Pawlik Timothy M, Rajasekera Priyani V, Schmidt Carl, Guttridge Denis, Hart Phil A. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 2018. DOI: 10.1016/j.pan.2018.11.002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.